Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 5
1999 12
2000 11
2001 14
2002 12
2003 12
2004 12
2005 8
2006 10
2007 10
2008 14
2009 11
2010 13
2011 13
2012 26
2013 26
2014 27
2015 35
2016 36
2017 40
2018 31
2019 40
2020 40
2021 39
2022 24
2023 14
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Results by year

Filters applied: . Clear all
Page 1
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Boorjian SA, et al. Among authors: bivalacqua tj. Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27. Lancet Oncol. 2021. PMID: 33253641 Free PMC article. Clinical Trial.
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Tan WS, et al. Among authors: bivalacqua tj. Eur Urol Oncol. 2022 Oct;5(5):505-516. doi: 10.1016/j.euo.2022.05.005. Epub 2022 Jun 17. Eur Urol Oncol. 2022. PMID: 35718695 Review.
In Reply.
Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR. Brennen WN, et al. Among authors: bivalacqua tj. Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. Stem Cells Transl Med. 2019. PMID: 30925030 Free PMC article. No abstract available.
Urinary Tissue Engineering: Challenges and Opportunities.
Singh A, Bivalacqua TJ, Sopko N. Singh A, et al. Among authors: bivalacqua tj. Sex Med Rev. 2018 Jan;6(1):35-44. doi: 10.1016/j.sxmr.2017.08.004. Epub 2017 Oct 21. Sex Med Rev. 2018. PMID: 29066225 Review.
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM, McConkey DJ, McGuire BM, Bivalacqua TJ, Kates M, Matoso A. Hoffman-Censits JH, et al. Among authors: bivalacqua tj. Appl Immunohistochem Mol Morphol. 2021 Sep 1;29(8):619-625. doi: 10.1097/PAI.0000000000000938. Appl Immunohistochem Mol Morphol. 2021. PMID: 33901032 Free PMC article.
Editorial Commentary.
Semerjian A, Bivalacqua TJ. Semerjian A, et al. Among authors: bivalacqua tj. Urol Pract. 2018 Sep;5(5):397. doi: 10.1016/j.urpr.2017.08.017. Epub 2018 Jun 27. Urol Pract. 2018. PMID: 37312356 No abstract available.
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: bivalacqua tj. J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. J Urol. 2020. PMID: 31821066
Reply by Authors.
Kohn TP, DuComb W, Sury K, Choi U, Bivalacqua TJ. Kohn TP, et al. Among authors: bivalacqua tj. Urol Pract. 2024 May;11(3):516. doi: 10.1097/UPJ.0000000000000551. Epub 2024 Apr 2. Urol Pract. 2024. PMID: 38564802 No abstract available.
Reply by Authors.
Harmatz IM, Alkhatib KY, Leff M, Nolazco JI, Michel KF, Slinger M, McLauchlan N, Cortese BD, Roberson DS, Schurhamer B, Lee DJ, Malkowicz SB, Trinh QD, Bivalacqua TJ, Guzzo TJ, Pierorazio PM. Harmatz IM, et al. Among authors: bivalacqua tj. Urol Pract. 2024 May;11(3):558. doi: 10.1097/UPJ.0000000000000568. Epub 2024 May 1. Urol Pract. 2024. PMID: 38560940 No abstract available.
Reply by Authors.
Harris TGW, Manyevitch R, Wu WJ, Leto Barone AA, Bivalacqua TJ, Burnett AL, Gearhart JP, Redett RJ 3rd. Harris TGW, et al. Among authors: bivalacqua tj. J Urol. 2021 Mar;205(3):887. doi: 10.1097/JU.0000000000001404.03. Epub 2020 Dec 31. J Urol. 2021. PMID: 33393832 No abstract available.
446 results